There exists a tremendous dependence on novel therapies that exceed VEGF to target the tumor blood supply.’ Related StoriesMeat-rich diet may increase kidney tumor riskNew findings reveal association between colorectal cancer and melanoma drug treatmentCrucial change in single DNA base predisposes children to aggressive form of cancerIn a phase 1, first-in-human clinical study, patients with advanced-stage tumors were treated with multiple ascending dosages of ACE-041, to judge the pharmacokinetics and safety of ACE-041. This study explored antitumor activity of ACE-041 also. Summary of interim results offered: ACE-041 subcutaneously injected once every three weeks is normally well-tolerated Common unwanted effects include gentle or moderate peripheral edema, fatigue, nausea, headaches, anorexia, and anemia.Overall, approximately one in five patients had at least 1 bleeding episode . The two groups did not differ significantly with respect to the incidence of mild, moderate, or heavy bleeding . The majority of bleeding occasions had been spontaneous, and the most frequent sites of bleeding had been gastrointestinal. The amounts of bleeding events and other adverse occasions were consistent across the prespecified subgroups defined by age, sex, race or ethnic group, kind of palliative surgery, times from palliation to randomization, and status with respect to aspirin use before or during the study.